Cell and Gene Meeting on Mesa - Genprex Transcript
Hello. My name is Michael Redman. I am the Executive Vice President and Chief Operations Officer of Genprex. We're a gene therapy company headquartered in Austin, Texas.
I may be making forward-looking statements in my presentation today. You're probably familiar with the Safe Harbor statement. And before you make any decision related to the company, please review this information.
Genprex offers new gene therapies that have the potential to change the treatment paradigm of major diseases like lung cancer and diabetes. We are focused on combination trials with blockbuster drugs. We believe we have validation because our recent fast track designation with our lead drug.
Genprex will continue to evaluate new technologies, new therapies, new indications, and always welcome new partners. The focus in 2021 will be to evaluate our lead drug, GPX-001, with the top two lung cancer drugs, Tagrisso and Keytruda. We believe our drug could be additive or synergistic due to the data that we found in our preclinical studies and also with our Phase 1
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |